MEI Pharma, Inc. (0JW9.L)
0JW9.L Stock Price Chart
Explore MEI Pharma, Inc. interactive price chart. Choose custom timeframes to analyze 0JW9.L price movements and trends.
0JW9.L Company Profile
Discover essential business fundamentals and corporate details for MEI Pharma, Inc. (0JW9.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
28.00
Website
https://www.meipharma.comCEO
Justin J. File CPA
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
0JW9.L Financial Timeline
Browse a chronological timeline of MEI Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 10 Nov 2025
Upcoming earnings on 17 Sept 2025
Earnings released on 13 May 2025
EPS came in at -$0.39.
Earnings released on 12 Feb 2025
EPS came in at -$0.40 surpassing the estimated -$2.20 by +81.82%.
Earnings released on 13 Nov 2024
EPS came in at -$1.20 surpassing the estimated -$1.70 by +29.41%.
Earnings released on 20 Sept 2024
EPS came in at -$2.76 falling short of the estimated -$1.41 by -96.38%.
Earnings released on 10 May 2024
EPS came in at -$1.37 surpassing the estimated -$1.49 by +7.86%.
Earnings released on 14 Feb 2024
EPS came in at -$1.66 falling short of the estimated -$1.41 by -17.48%.
Dividend declared on 16 Nov 2023
A dividend of $1.75 per share was announced, adjusted to $1.75. The dividend was paid on 6 Dec 2023.
Earnings released on 10 Nov 2023
EPS came in at $8.46 surpassing the estimated -$1.80 by +571.31%, while revenue for the quarter reached $65.30M.
Earnings released on 27 Sept 2023
EPS came in at -$1.51 surpassing the estimated -$2.80 by +46.18%, while revenue for the quarter reached $1.46M, beating expectations by +134.75%.
Earnings released on 12 May 2023
EPS came in at -$2.32 surpassing the estimated -$2.90 by +20.10%, while revenue for the quarter reached $5.89M, beating expectations by +1.60K%.
Stock split effective on 17 Apr 2023
Shares were split 1:20, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Feb 2023
EPS came in at $1.54 surpassing the estimated -$3.03 by +150.77%, while revenue for the quarter reached $32.74M, beating expectations by +640.72%.
Earnings released on 30 Sept 2022
EPS came in at -$2.50 surpassing the estimated -$3.35 by +25.52%, while revenue for the quarter reached $8.73M, beating expectations by +97.60%.
Earnings released on 30 Jun 2022
EPS came in at -$2.41 surpassing the estimated -$3.85 by +37.33%, while revenue for the quarter reached $11.41M, beating expectations by +138.95%.
Earnings released on 31 Mar 2022
EPS came in at -$1.31 surpassing the estimated -$3.67 by +64.28%, while revenue for the quarter reached $9.69M, beating expectations by +181.89%.
Earnings released on 31 Dec 2021
EPS came in at -$1.90, while revenue for the quarter reached $11.83M.
Earnings released on 30 Sept 2021
EPS came in at -$2.09 surpassing the estimated -$3.78 by +44.79%, while revenue for the quarter reached $13.39M, beating expectations by +154.43%.
Earnings released on 30 Jun 2021
EPS came in at -$0.98, while revenue for the quarter reached $10.12M.
Earnings released on 31 Mar 2021
EPS came in at -$5.56, while revenue for the quarter reached $2.42M.
Earnings released on 31 Dec 2020
EPS came in at -$1.40, while revenue for the quarter reached $12.60M.
Earnings released on 30 Sept 2020
EPS came in at $0.12, while revenue for the quarter reached $6.64M.
0JW9.L Stock Performance
Access detailed 0JW9.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.